DDX53 and neoplasm: In vivo efficacy studies involved treatment of CT26 and MCA205 (a weakly immunogenic fibrosarcoma derived cell line) tumour bearing mice with the EphA2-PBD or EphA2-Tub conjugates, resulting in a large percentage of CRs.